

# A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

NCT06588686

---

Status	RECRUITING
Phase	Phase 2
Sponsor	Vicore Pharma AB
Enrollment	360 participants

## Key Eligibility Criteria

---

### Inclusion (15)

- Age e 40 years at the time of signing the informed consent.
- Diagnosed with IPF within 7 years prior to visit 1, as per applicable ATS/ERS/JRS/ALAT guidelines at the time of diagnosis.
- HRCT scan within 36 months prior to visit 1 with central reading confirming either a or b, and c
- A pattern consistent with usual interstitial pneumonia (UIP) according to ATS/ERS/JRS/ALAT 2022 guideline (Raghu et al., 2022) UIP or probable UIP.
- A pattern indeterminate for UIP according to ATS/ERS/JRS/ALAT 2022 guidelines (Raghu et al., 2022) and a historical biopsy (surgical lung biopsy or transbronchial lung cryobiopsy) consistent with IPF.

... and 10 more (see full listing online)

### Exclusion (18)

- Participants are excluded from the trial if any of the following criteria apply:
- Concurrent serious medical condition that in the opinion of the investigator constitutes a risk or a contraindication for participation in the trial or that could interfere with the trial objectives, conduct or evaluation, including active or suspected malignancy or history of malignancy within 5 years prior to visit 1, except appropriately treated basal cell carcinoma of the skin, fully resected and cured squamous cell carcinoma of the skin, "under surveillance" prostate cancer or in situ carcinoma of uterine cervix.
- Airways obstruction with a pre-bronchodilator forced expiratory volume in one second (FEV1)/FVC ratio  $\leq 0.7$  at visit 1.
- Lower respiratory tract infection requiring antibiotics and not fully recovered according to investigator judgement within 4 weeks prior to visit 2.
- Confirmed infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requiring hospitalization and not fully recovered according to investigator judgement within 4 weeks prior to visit 2.

... and 13 more (see full listing online)

## Locations (117 total)

---

UAB Hospital, School of Medicine/Lung Health Center, Birmingham, Alabama, United States  
Keck Medicine of University of Southern California, Los Angeles, California, United States  
Paradigm Clinical Research Centers, Inc., Redding, California, United States

... and 114 more locations